KR101166738B1 - 프로스타글란딘 화합물 - Google Patents

프로스타글란딘 화합물 Download PDF

Info

Publication number
KR101166738B1
KR101166738B1 KR1020117017023A KR20117017023A KR101166738B1 KR 101166738 B1 KR101166738 B1 KR 101166738B1 KR 1020117017023 A KR1020117017023 A KR 1020117017023A KR 20117017023 A KR20117017023 A KR 20117017023A KR 101166738 B1 KR101166738 B1 KR 101166738B1
Authority
KR
South Korea
Prior art keywords
compound
alkyl
group
hydrogen
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020117017023A
Other languages
English (en)
Korean (ko)
Other versions
KR20110087351A (ko
Inventor
류지 우에노
츠요시 하베
다카시 세키다
Original Assignee
가부시키가이샤 아루떼꾸 우에노
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34135320&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101166738(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 가부시키가이샤 아루떼꾸 우에노 filed Critical 가부시키가이샤 아루떼꾸 우에노
Publication of KR20110087351A publication Critical patent/KR20110087351A/ko
Application granted granted Critical
Publication of KR101166738B1 publication Critical patent/KR101166738B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020117017023A 2003-08-12 2004-08-12 프로스타글란딘 화합물 Expired - Fee Related KR101166738B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49412103P 2003-08-12 2003-08-12
US60/494,121 2003-08-12
PCT/JP2004/011864 WO2005013928A1 (en) 2003-08-12 2004-08-12 Composition and method for promoting hair growth

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020067002643A Division KR101137750B1 (ko) 2003-08-12 2004-08-12 육모 촉진용 조성물 및 그 방법

Publications (2)

Publication Number Publication Date
KR20110087351A KR20110087351A (ko) 2011-08-02
KR101166738B1 true KR101166738B1 (ko) 2012-07-23

Family

ID=34135320

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020117031353A Ceased KR20120008080A (ko) 2003-08-12 2004-08-12 육모 촉진용 조성물 및 그 방법
KR1020117017023A Expired - Fee Related KR101166738B1 (ko) 2003-08-12 2004-08-12 프로스타글란딘 화합물
KR1020067002643A Expired - Fee Related KR101137750B1 (ko) 2003-08-12 2004-08-12 육모 촉진용 조성물 및 그 방법

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020117031353A Ceased KR20120008080A (ko) 2003-08-12 2004-08-12 육모 촉진용 조성물 및 그 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020067002643A Expired - Fee Related KR101137750B1 (ko) 2003-08-12 2004-08-12 육모 촉진용 조성물 및 그 방법

Country Status (15)

Country Link
US (2) US8686035B2 (enExample)
EP (2) EP2243771A3 (enExample)
JP (2) JP4642021B2 (enExample)
KR (3) KR20120008080A (enExample)
CN (1) CN1867310B (enExample)
AT (1) ATE526008T1 (enExample)
CA (1) CA2534645C (enExample)
CY (1) CY1112076T1 (enExample)
DK (1) DK1673058T3 (enExample)
ES (1) ES2369892T3 (enExample)
PL (1) PL1673058T3 (enExample)
PT (1) PT1673058E (enExample)
SI (1) SI1673058T1 (enExample)
TW (2) TWI348386B (enExample)
WO (1) WO2005013928A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI348386B (en) 2003-08-12 2011-09-11 R Tech Ueno Ltd Composition and method for promoting hair growth
EP1830793A1 (en) 2004-12-29 2007-09-12 R-Tech Ueno, Ltd. Composition and method for scalp and hair treatment
US8455547B2 (en) * 2008-02-05 2013-06-04 Allergan, Inc. Substituted cyclopentanes having prostaglandin activity
US7964596B2 (en) * 2008-03-07 2011-06-21 Allergan, Inc. Therapeutic compounds
US7732443B2 (en) * 2008-03-18 2010-06-08 Yariv Donde Therapeutic substituted cyclopentanes
BRPI0912193A2 (pt) * 2008-05-09 2015-10-06 Allergan Inc compostos terapêuticos.
EP2538963B8 (en) * 2010-02-24 2017-08-02 Advangen International Pty Ltd Method of treatment or prevention of hair loss or for the enhancement of hair growth
JPWO2012176792A1 (ja) * 2011-06-21 2015-02-23 株式会社アールテック・ウエノ 炎症性疾患、アレルギー性疾患および自己免疫疾患用途のための医薬組成物
WO2014182908A1 (en) * 2013-05-10 2014-11-13 Topical Solutions, Inc. Compositions and methods for treating nails, claws, and hoofs
CA3140841C (en) 2019-08-07 2025-05-06 Aneira Pharma, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF HAIR LOSS

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2328132A1 (de) * 1973-05-30 1975-01-02 Schering Ag Neue prostansaeurederivate und verfahren zu ihrer herstellung
DE2434133C2 (de) * 1974-07-12 1987-03-19 Schering AG, 1000 Berlin und 4709 Bergkamen 15,15-Äthylendioxy-Prostansäurederivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
CS230650B1 (cs) 1983-01-14 1984-08-13 Jan Stanek Způsob výroby acetalů prostanoidů
DE3325175A1 (de) 1983-07-08 1985-01-17 Schering AG, 1000 Berlin und 4709 Bergkamen 11-halogen-prostanderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
JPH0818989B2 (ja) * 1984-01-12 1996-02-28 株式会社ミドリ十字 脂肪乳剤中のプロスタグランジンの安定化方法
JPS61218510A (ja) * 1985-03-22 1986-09-29 Dai Ichi Seiyaku Co Ltd 毛髪用剤
US5166174A (en) * 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
CA1322749C (en) * 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US5428062A (en) * 1987-01-28 1995-06-27 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
US5591887A (en) * 1987-04-30 1997-01-07 R-Tech Ueno, Ltd. Prostaglandins of the F series
CA1324129C (en) * 1987-04-30 1993-11-09 Ryuzo Ueno Prostaglandins of the f series
US5221763A (en) * 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
DE3876050T2 (de) * 1987-09-18 1993-03-25 Ueno Seiyaku Oyo Kenkyujo Kk Okulare hypotensivagenzien.
US5166178B1 (en) * 1987-09-18 1998-07-21 R Tech Ueno Ltd Ocular hypotensive agents
US5212200A (en) * 1987-09-18 1993-05-18 R-Tech Ueno, Ltd. Ocular hypotensive agents
CA2039420C (en) * 1990-04-04 1996-12-10 Ryuji Ueno Treatment of cataract with 15-keto-prostaglandin compounds
US5175189A (en) * 1990-05-22 1992-12-29 K.K. Ueno Seiyaku Oyo Kenkyujo Treatment of ocular hypertension with a synergistic combination for ophthalmic use
ATE117208T1 (de) * 1990-05-22 1995-02-15 R Tech Ueno Ltd Behandlung von intraokularem druck mit einer ophthalmischen synergistischen kombination.
US5166175A (en) * 1990-05-22 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Treatment of ocular hypertension with a synergistic combination
DK0458588T3 (da) * 1990-05-22 1995-03-13 R Tech Ueno Ltd Behandling af okulær hypertension med en synergistisk kombination til okulær administration
TW210287B (enExample) * 1991-03-01 1993-08-01 Kabushikaisha Ueno Seiyaku Oyo Kenkyujo
US5274130A (en) * 1991-09-03 1993-12-28 R-Tech Ueno Ltd. Process for production of prostaglandin intermediates
EP0561073B1 (en) * 1992-03-19 2001-10-24 R-Tech Ueno Ltd. Treatment of ocular hypertension with beta-blockers and derivatives of prostanoic acid
EP0668076B1 (en) * 1992-08-26 2002-09-04 Sucampo AG Stabilization of a prostanoic acid compound
SE9303444D0 (sv) 1993-10-20 1993-10-20 Kabi Pharmacia Ab New use of prostaglandins
SE9402816D0 (sv) * 1994-08-24 1994-08-24 Pharmacia Ab Method and meams for drug administration
EP0857718B1 (en) * 1996-06-10 2002-08-14 Sucampo AG Endothelin antagonist
WO1998000100A1 (en) * 1996-07-03 1998-01-08 The Board Of Regents Of The University Of Oklahoma Enhancement of skin pigmentation by prostaglandins
WO1998020881A1 (en) * 1996-11-12 1998-05-22 Alcon Laboratories, Inc 15-ketal prostaglandins for the treatment of glaucoma or ocular hypertension
DE69823852T2 (de) * 1997-02-04 2005-05-19 Johnstone, Murray A., Seattle Verfahren zur förderung des haarwuchses und entwicklung des haarsystems
JP3217293B2 (ja) * 1997-04-17 2001-10-09 株式会社アールテック・ウエノ 発毛・育毛剤
US6235781B1 (en) * 1998-07-14 2001-05-22 Alcon Laboratories, Inc. Prostaglandin product
US6225348B1 (en) * 1998-08-20 2001-05-01 Alfred W. Paulsen Method of treating macular degeneration with a prostaglandin derivative
KR100830061B1 (ko) * 1999-10-15 2008-05-16 수캄포 아게 이환식 화합물 조성물 및 이의 안정화 방법
US20020037914A1 (en) * 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020172693A1 (en) * 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020146439A1 (en) * 2000-03-31 2002-10-10 Delong Mitchell Anthony Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins
FR2812191B1 (fr) * 2000-07-28 2003-10-17 Oreal Utilisation d'agonistes du recepteur des prostaglandines e2 (ep-3) pour attenuer, diminuer ou stopper la pousse des cheveux et des poils dans des preparations cosmetiques
FR2812193B1 (fr) * 2000-07-28 2003-10-24 Oreal Utilisation d'antagoniste des recepteurs des prostaglandines ep-2 et/ou ep-4 pour attenuer, diminuer ou stopper la pousse des cheveux et des poils dans des preparations cosmetiques
FR2812190B1 (fr) * 2000-07-28 2003-01-31 Oreal Utilisation d'agonistes non prostanoiques des recepteurs des prostaglandines ep-2 et/ou ep-4 comme agent cosmetique permettant d'attenuer, de diminuer ou d'arreter la chute des cheveux et des poils
FR2812192B1 (fr) * 2000-07-28 2003-01-31 Oreal Utilisation d'antagonistes de recepteur des prostaglandines ep-3 comme agent cosmetique permettant d'attenuer, de diminuer ou d'arreter la chute des cheveux et des poils
US6414016B1 (en) * 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
SE0100158D0 (sv) * 2001-01-19 2001-01-19 Synphora Ab Novel method and composition for local treatment of Meniere´s disease and tinnitus
MXPA04002006A (es) 2001-08-31 2004-06-07 Sucampo Ag Analogos de prostagladina como abridor del canal de cloruro.
JP2003155218A (ja) * 2001-09-10 2003-05-27 Lion Corp 養育毛組成物
US7351404B2 (en) * 2002-02-04 2008-04-01 Allergan, Inc. Method of enhancing hair growth
US20030199590A1 (en) * 2002-07-25 2003-10-23 Cagle Gerald D Prostaglandin analogues for promotion of hair growth
US20040115234A1 (en) * 2002-09-24 2004-06-17 Gewirtz Joan T. Cosmetic composition
TWI348386B (en) 2003-08-12 2011-09-11 R Tech Ueno Ltd Composition and method for promoting hair growth
US20050112075A1 (en) * 2003-11-25 2005-05-26 Hwang Cheng S. Reduction of hair growth
EP1830793A1 (en) * 2004-12-29 2007-09-12 R-Tech Ueno, Ltd. Composition and method for scalp and hair treatment
EP1864666B1 (en) * 2005-03-31 2012-08-15 Asahi Glass Company, Limited Protective agent for retinal neuronal cell containing prostaglandin f2 alpha derivative as active ingredient
JP5780690B2 (ja) 2005-08-25 2015-09-16 大正製薬株式会社 発毛剤組成物
US20070160562A1 (en) * 2006-01-06 2007-07-12 Brinkenhoff Michael C Delivery devices for hair-promoting cosmetic agent
US20070286890A1 (en) * 2006-06-07 2007-12-13 John Garnett Walt Eyelash applicator and method
US8206695B2 (en) * 2007-04-26 2012-06-26 La Canada Ventures, Inc. Eyelash enhancement composition and method of treatment
US20090018204A1 (en) * 2007-07-13 2009-01-15 Brinkenhoff Michael C Composition and method for enhancing hair growth
WO2009035565A1 (en) 2007-09-07 2009-03-19 Qlt Plug Delivery, Inc Prostaglandin analogues for implant devices and methods
US20090088473A1 (en) * 2007-09-28 2009-04-02 Cayman Chemical Company Method for screening of prostaglandin compounds comprising an optimal formulation for the enhancement of hair growth and the stimulation of follicular anagen and formulations resulting therefrom
WO2009054787A1 (en) * 2007-10-26 2009-04-30 Astrazeneca Ab 1,2,4-triazole carboxylic acid derivatives as modulators of mglur5
JP2011502152A (ja) * 2007-10-31 2011-01-20 パメラ リプキン プロスタグランジン類似体組成物及び上皮関連症状の治療方法
CA2724340A1 (en) 2008-05-14 2009-11-19 Peter Thomas Roth Labs, Llc Prostaglandin based compositions and method of use thereof
US20080275118A1 (en) * 2008-06-12 2008-11-06 Shaw Mari M Health and cosmetic composition and regime for stimulating hair growth and thickening on the head, including the scalp, eyelashes, and eyebrows, and which discourages hair loss

Also Published As

Publication number Publication date
JP4642021B2 (ja) 2011-03-02
KR20110087351A (ko) 2011-08-02
DK1673058T3 (da) 2011-10-24
CA2534645C (en) 2013-05-07
EP2243771A3 (en) 2011-01-12
EP1673058A1 (en) 2006-06-28
US20140171496A1 (en) 2014-06-19
CY1112076T1 (el) 2015-12-09
US20080033036A1 (en) 2008-02-07
KR20120008080A (ko) 2012-01-25
CN1867310B (zh) 2010-06-16
ATE526008T1 (de) 2011-10-15
TW201039831A (en) 2010-11-16
TWI495471B (zh) 2015-08-11
PT1673058E (pt) 2011-10-12
WO2005013928A1 (en) 2005-02-17
PL1673058T3 (pl) 2012-02-29
CA2534645A1 (en) 2005-02-17
ES2369892T3 (es) 2011-12-07
HK1098949A1 (en) 2007-08-03
TWI348386B (en) 2011-09-11
SI1673058T1 (sl) 2011-11-30
JP2011012076A (ja) 2011-01-20
TW200505494A (en) 2005-02-16
KR20060058708A (ko) 2006-05-30
CN1867310A (zh) 2006-11-22
KR101137750B1 (ko) 2012-04-24
JP2007518685A (ja) 2007-07-12
EP1673058B1 (en) 2011-09-28
JP5318837B2 (ja) 2013-10-16
EP2243771A2 (en) 2010-10-27
US8686035B2 (en) 2014-04-01

Similar Documents

Publication Publication Date Title
JP5318837B2 (ja) 育毛を促進する組成物および方法
US20140194497A1 (en) Composition and method for scalp and hair treatment
KR101354771B1 (ko) 중추 신경계 질환 치료를 위한 방법 및 조성물
AU2017203092B2 (en) Method for treating schizophrenia
HK1149252A (en) Composition and method for promoting hair growth
HK1098949B (en) Composition and method for promoting hair growth
KR20120031954A (ko) 클라우딘 매개 기능을 조정하고 피부 장애를 치료하는데 사용하기 위한 프로스타글란딘 유도체를 포함하는 제약 조성물
EP2730283A1 (en) Pharmaceutical composition for inflammatory diseases, allergic diseases and autoimmune diseases
JP2010126475A (ja) 白髪防止剤
HK1196278A (en) Method for treating schizophrenia

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20150604

Year of fee payment: 4

PR1001 Payment of annual fee

Fee payment year number: 4

St.27 status event code: A-4-4-U10-U11-oth-PR1001

FPAY Annual fee payment

Payment date: 20160523

Year of fee payment: 5

PR1001 Payment of annual fee

Fee payment year number: 5

St.27 status event code: A-4-4-U10-U11-oth-PR1001

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

Not in force date: 20170713

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

St.27 status event code: A-4-4-U10-U13-oth-PC1903

PC1903 Unpaid annual fee

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20170713

St.27 status event code: N-4-6-H10-H13-oth-PC1903